GBS GLUCOSE BIOSENSOR SYS

Intelligent Bio Solutions to Host Virtual Fireside Chat on Wednesday, December 11th at 4:30 p.m. ET

Intelligent Bio Solutions to Host Virtual Fireside Chat on Wednesday, December 11th at 4:30 p.m. ET

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it will host a virtual fireside chat with Harry Simeonidis, President & CEO and Spiro Sakiris, CFO at 4:30 p.m. ET on December 11, 2024.

During the event, management will discuss the Company's recent clinical study results, path to FDA 510(k) submission, and offer investors an opportunity to ask questions.

Virtual Fireside Chat Details:

Dates: December 11, 2024

Presentation Time: 4:30 p.m. ET

Registration Link:

A Q&A portion will occur at the end of the call and a link to the recording of the presentation will be available on INBS’ after the event.

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

For more information, visit: 

Company Contact:

Intelligent Bio Solutions Inc.

Investor & Media Contact: 

Valter Pinto, Managing Director 

KCSA Strategic Communications 

PH: (212) 896-1254 



EN
04/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GLUCOSE BIOSENSOR SYS

 PRESS RELEASE

Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter ...

Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter Revenue with Double-Digit Sequential and Year-Over-Year Growth and Strong Operational Momentum Company anticipates fiscal fourth quarter sequential and year-on-year revenue growth of approximately 16% Company advanced efforts to secure U.S. FDA 510(k) clearance for planned U.S. market entry and strengthened global readiness through system upgrades and localization NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering...

 PRESS RELEASE

Intelligent Bio Solutions Secures Major Drug Testing Tender with Leadi...

Intelligent Bio Solutions Secures Major Drug Testing Tender with Leading London Transport Operator NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major contract with one of London's largest public transport operators, spanning 14 operational sites in greater London and employing over 4,400 staff. INBS's Intelligent Fingerprinting Drug Screening System will be deployed across a multi-garage bus ne...

 PRESS RELEASE

Intelligent Bio Solutions Inc. Enters Into Agreements to Raise $3.8 Mi...

Intelligent Bio Solutions Inc. Enters Into Agreements to Raise $3.8 Million in Gross Proceeds Proceeds to Fund Completion of the Company’s 510k Filing with the U.S. FDA for its Fingerprint Drug Screening System NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced an agreement between the Company and several current warrant holders to exercise (or prepay the exercise price) certain existing warrants to purchase up to 2...

 PRESS RELEASE

Intelligent Bio Solutions to Strengthen FDA 510(k) Submission with New...

Intelligent Bio Solutions to Strengthen FDA 510(k) Submission with New Positive Data Demonstrating Ultra-Precise Fingerprint Sweat Detection and Platform Resilience Data confirms Company’s ability to detect trace sweat volumes at ultra-micro level System demonstrates resilience across diverse conditions NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful collection of new data that further reinforces t...

 PRESS RELEASE

Intelligent Bio Solutions Accelerates Global Growth with SmarTest® Pat...

Intelligent Bio Solutions Accelerates Global Growth with SmarTest® Patch Agreement, Reinforces U.S. Expansion Path as FDA Approval Remains a Strategic Priority NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a new global distribution agreement with SMARTOX®, a Texas-based leader in drug and alcohol screening services, to bring its SmarTest Patch drug detection product to international markets outside of the United ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch